<p>Mechanisms of acquired resistance to immune checkpoint inhibitors (ICIs) are poorly understood. The purpose of this study was to investigate whether alterations in genes encoding components of the HLA Class I antigen processing and presentation machinery or interferon signaling pathways play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Whole exome sequencing was performed on tumor samples collected from patients with advanced non-small cell lung cancer at the time of resistance to PD-1 axis inhibitors and on available matched pre-treatment and normal samples. Patient-derived xenografts successfully established from the ICI-resistant samples were also exome sequenced. Additionally, RNA sequencing was performed on cases with sufficient tissue.</p>

Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Carcinoma, Non-Small-Cell Lung study with RNA-Seq, WXS data on dbGaP (14 participants)

Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer

Description

Applying For Access

Summary